CareDx achieved a 25% year-over-year revenue increase in Q4 2025, reaching $108.4 million. While the company reported a GAAP net loss of $4.1 million, it maintained positive adjusted EBITDA and strong cash flow from operations, ending the year with a solid cash position of approximately $200 million.

CareDx reported a strong first quarter 2025, with total revenue increasing 18% year-over-year to $84.7 million. The company achieved its seventh consecutive quarter of sequential testing services volume growth and significantly improved its adjusted EBITDA to $4.6 million from a loss in the prior year.

CareDx announced a transformative year in 2024, achieving significant revenue growth and a return to profitability. The company reported a 32% year-over-year increase in Q4 revenue to $86.6 million and a 19% increase in full-year revenue to $333.8 million. Net income for Q4 was $87.7 million, a substantial improvement from a net loss in the prior year.

CareDx reported a strong third quarter with a 23% increase in total revenue year-over-year, reaching $82.9 million. The company achieved positive adjusted EBITDA for the second consecutive quarter and raised its full year revenue guidance to $327 to $331 million.

CareDx announced a strong second quarter with significant revenue growth of 31% year-over-year, driven by growth across all business segments. The company reported a net loss of $1.4 million but a non-GAAP net income of $13.6 million, and positive adjusted EBITDA of $12.9 million. They also raised the 2024 revenue guidance to $320 to $328 million and adjusted EBITDA to a gain of $9 to $15 million.

CareDx reported a decrease of 7% in revenue compared to Q1 2023, but a 10% increase compared to Q4 2023. The company is raising its full year 2024 revenue guidance to $274 million to $282 million.

CareDx reported a decrease in revenue for the fourth quarter of 2023, with a net loss that included a significant accrual related to alleged patent infringement. The company is focusing on delivering clinical and digital solutions to improve allograft survival and expanding payer coverage.

CareDx reported a 15% decrease in revenue compared to the third quarter of 2022, but a 7% increase compared to the second quarter of 2023, excluding a Medicare claims billing adjustment. Testing services saw a slight increase in patient results compared to the previous quarter. The company raised its revenue guidance for the full year 2023 to $274 to $278 million.

CareDx reported a 13% year-over-year decrease in revenue to $70.3 million for Q2 2023, primarily due to the impact of Medicare Billing Article revisions. The company achieved key milestones, including Medicare coverage for HeartCare and AlloSure Lung. They also reached over 80% adoption of new test requisition forms ahead of schedule.

CareDx reported a decrease in revenue due to billing article revisions, which impacted AlloSure Kidney Medicare tests. Despite this, the company achieved record patient test results for AlloMap and AlloSure, and record revenue for its Patient and Digital Solutions business. The company is withdrawing its 2023 revenue guidance due to uncertainties related to billing article revisions.

CareDx reported a 4% increase in revenue for Q4 2022, reaching $82.4 million. The company focused on key initiatives such as improving cash collections and expanding coverage, while also managing a net loss and adjusted EBITDA loss for the quarter.

CareDx reported a 5% year-over-year increase in revenue, reaching $79.4 million for the third quarter of 2022. The company is on track to achieve profitable growth with positive adjusted EBITDA by the first half of 2023.

CareDx reported a revenue increase of 9% year-over-year, reaching $80.6 million. The company delivered 45,000 patient test results, a 21% increase compared to Q2 2021. However, the company experienced a net loss of $21.7 million, compared to a net loss of $1.9 million in the same period last year.

CareDx reported a strong first quarter in 2022, with revenue reaching $79.4 million, an 18% increase compared to the same period last year. The company saw growth across all its revenue segments, including testing services, product revenue, and patient and digital solutions. However, the company experienced a net loss of $19.6 million, a significant increase compared to the net loss of $0.7 million in the first quarter of 2021.

CareDx reported a 35% increase in revenue for Q4 2021, reaching $79.2 million, driven by growth in testing services, product revenue, and patient and digital solutions. The company's net loss increased to $16.2 million, compared to a net loss of $3.5 million in the same period of 2020. AlloSure and AlloMap patient results grew by 67% year-over-year, and the company launched AlloSure Lung testing service. CareDx completed acquisitions of MedActionPlan and The Transplant Pharmacy.

CareDx reported a strong third quarter with record revenue of $75.6 million, a 42% increase year-over-year. Testing services volume grew 86% year-over-year. The company increased its full-year revenue guidance to $290 million to $293 million.

CareDx reported a strong second quarter in 2021, with a 77% increase in revenue compared to the same period last year. The company's total revenue reached $74.2 million, driven by growth in testing services and product revenue. They increased full year revenue guidance to $280 million to $290 million.

CareDx achieved a record first quarter with total revenue of $67.4 million, a 76% increase year-over-year. The company raised its full year 2021 revenue guidance to $270 million to $280 million.

CareDx reported a strong fourth quarter, with a 64% increase in revenue compared to the prior year. The company also achieved record full-year revenue growth and made progress in expanding its services and solutions for transplant patients.

CareDx reported a strong third quarter, achieving a 58% year-over-year revenue increase to $53.4 million. The company also saw a rise in non-GAAP net income to $5.1 million and provided over 21,800 AlloSure Kidney and AlloMap Heart patient results.

CareDx reported a 33% year-over-year increase in total revenue, reaching $41.8 million for the quarter ended June 30, 2020. The company's net loss was $6.6 million, with a non-GAAP net income of $1.7 million.

CareDx reported a strong first quarter with a 48% year-over-year increase in total revenue, reaching $38.4 million. The company saw growth in testing services, product revenue, and digital solutions. While the net loss was $5.8 million, non-GAAP net income was $0.2 million. Due to COVID-19 uncertainties, CareDx withdrew its 2020 guidance on April 8, 2020.

CareDx reported a strong Q4 2019 with a 52% increase in revenue compared to Q4 2018. The company also saw growth in testing services, product revenue, and digital revenue. While GAAP net loss was reported, non-GAAP net income and adjusted EBITDA were positive.